To include your compound in the COVID-19 Resource Center, submit it here.

Tivantinib: Phase III started

Kyowa Hakko began the double-blind, Asian Phase III ATTENTION trial to compare twice-daily oral tivantinib plus once-daily oral erlotinib

Read the full 191 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE